207 related articles for article (PubMed ID: 28550080)
41. A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY).
Pergola PE; Rosenbaum DP; Yang Y; Chertow GM
J Am Soc Nephrol; 2021 Jun; 32(6):1465-1473. PubMed ID: 33766811
[TBL] [Abstract][Full Text] [Related]
42. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study.
Ramos R; Moreso F; Borras M; Ponz E; Buades JM; Teixidó J; Morey A; Garcia C; Vera M; Doñate MT; de Arellano MR; Barbosa F; González MT
Perit Dial Int; 2007; 27(6):697-701. PubMed ID: 17984434
[TBL] [Abstract][Full Text] [Related]
43. Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients.
Imtiaz R; Hawken S; McCormick BB; Leung S; Hiremath S; Zimmerman DL
Nutrients; 2017 Feb; 9(2):. PubMed ID: 28218647
[TBL] [Abstract][Full Text] [Related]
44. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis.
Jamal SA; Vandermeer B; Raggi P; Mendelssohn DC; Chatterley T; Dorgan M; Lok CE; Fitchett D; Tsuyuki RT
Lancet; 2013 Oct; 382(9900):1268-77. PubMed ID: 23870817
[TBL] [Abstract][Full Text] [Related]
45. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
46. Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial.
Yin J; Yin J; Lian R; Li P; Zheng J
BMC Nephrol; 2021 Jul; 22(1):243. PubMed ID: 34210293
[TBL] [Abstract][Full Text] [Related]
47. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
[TBL] [Abstract][Full Text] [Related]
48. Calcium-enriched bread for treatment of uremic hyperphosphatemia.
Babarykin D; Adamsone I; Amerika D; Spudass A; Moisejev V; Berzina N; Michule L; Rozental R
J Ren Nutr; 2004 Jul; 14(3):149-56. PubMed ID: 15232793
[TBL] [Abstract][Full Text] [Related]
49. Mild hyperphosphatemia and mortality in hemodialysis patients.
Rodriguez-Benot A; Martin-Malo A; Alvarez-Lara MA; Rodriguez M; Aljama P
Am J Kidney Dis; 2005 Jul; 46(1):68-77. PubMed ID: 15983959
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
[TBL] [Abstract][Full Text] [Related]
51. Mortality in kidney disease patients treated with phosphate binders: a randomized study.
Di Iorio B; Bellasi A; Russo D;
Clin J Am Soc Nephrol; 2012 Mar; 7(3):487-93. PubMed ID: 22241819
[TBL] [Abstract][Full Text] [Related]
52. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
Koiwa F; Terao A
Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
[TBL] [Abstract][Full Text] [Related]
53. Meal phosphate variability does not support fixed dose phosphate binder schedules for patients treated with peritoneal dialysis: a prospective cohort study.
Leung S; McCormick B; Wagner J; Biyani M; Lavoie S; Imtiaz R; Zimmerman D
BMC Nephrol; 2015 Dec; 16():205. PubMed ID: 26645271
[TBL] [Abstract][Full Text] [Related]
54. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial.
Dwyer JP; Sika M; Schulman G; Chang IJ; Anger M; Smith M; Kaplan M; Zeig S; Koury MJ; Blumenthal SS; Lewis JB;
Am J Kidney Dis; 2013 May; 61(5):759-66. PubMed ID: 23369827
[TBL] [Abstract][Full Text] [Related]
55. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
[TBL] [Abstract][Full Text] [Related]
56. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool.
Galassi A; Cupisti A; Santoro A; Cozzolino M
J Nephrol; 2015 Aug; 28(4):415-29. PubMed ID: 25245472
[TBL] [Abstract][Full Text] [Related]
57. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
Chang YM; Tsai SC; Shiao CC; Liou HH; Yang CL; Tung NY; Hsu KS; Chen IL; Liu MC; Kao JL; Jhen RN; Huang YT
Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
[TBL] [Abstract][Full Text] [Related]
58. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial.
Walsh M; Manns BJ; Klarenbach S; Tonelli M; Hemmelgarn B; Culleton B
Hemodial Int; 2010 Apr; 14(2):174-81. PubMed ID: 20041960
[TBL] [Abstract][Full Text] [Related]
59. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
60. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]